GlaxoSmithKline Secures Exclusive Rights to Syndivia's Prostate Cancer ADC in $268M Deal

Deep News

Oct 27

Shares of GlaxoSmithKline PLC (GSK) rose 1.9% in early Monday trading following the company's announcement of a licensing agreement with Syndivia. The deal grants GSK exclusive global rights to develop and commercialize Syndivia's preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC), with potential milestone payments reaching £268 million.

This agreement strengthens GlaxoSmithKline's oncology pipeline, particularly in advanced prostate cancer therapeutics. The ADC candidate represents a promising addition to GSK's existing cancer treatment portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1176058865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176058865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176058865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176058865","market":"sg","top_or_hot":-1,"title":"GlaxoSmithKline Secures Exclusive Rights to Syndivia's Prostate Cancer ADC in $268M Deal","media":"Deep News","content":"<p>Shares of GlaxoSmithKline PLC (GSK) rose 1.9% in early Monday trading following the company's announcement of a licensing agreement with Syndivia. The deal grants GSK exclusive global rights to develop and commercialize Syndivia's preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC), with potential milestone payments reaching £268 million.</p>\n<p>This agreement strengthens GlaxoSmithKline's oncology pipeline, particularly in advanced prostate cancer therapeutics. The ADC candidate represents a promising addition to GSK's existing cancer treatment portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline Secures Exclusive Rights to Syndivia's Prostate Cancer ADC in $268M Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline Secures Exclusive Rights to Syndivia's Prostate Cancer ADC in $268M Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-27 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GlaxoSmithKline PLC (GSK) rose 1.9% in early Monday trading following the company's announcement of a licensing agreement with Syndivia. The deal grants GSK exclusive global rights to develop and commercialize Syndivia's preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC), with potential milestone payments reaching £268 million.</p>\n<p>This agreement strengthens GlaxoSmithKline's oncology pipeline, particularly in advanced prostate cancer therapeutics. The ADC candidate represents a promising addition to GSK's existing cancer treatment portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"","article_id":"1176058865","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176058865","pubTimestamp":1761576616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of GlaxoSmithKline PLC (GSK) rose 1.9% in early Monday trading following the company's announcement of a licensing agreement with Syndivia. The deal grants GSK exclusive global rights to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4007":"制药","GSK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK.UK":"葛兰素史克"},"translate_title":"葛兰素史克以2.68亿美元的交易获得Syndivia前列腺癌ADC的独家权利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":1,"GSK":1},"content_text":"Shares of GlaxoSmithKline PLC (GSK) rose 1.9% in early Monday trading following the company's announcement of a licensing agreement with Syndivia. The deal grants GSK exclusive global rights to develop and commercialize Syndivia's preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC), with potential milestone payments reaching £268 million.\nThis agreement strengthens GlaxoSmithKline's oncology pipeline, particularly in advanced prostate cancer therapeutics. The ADC candidate represents a promising addition to GSK's existing cancer treatment portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}